The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients

Antiviral Therapy

Volumn 15, Issue 1, 2010, Pages 91-99

  Amorosa, Valerianna K ^a,b   Slim, Jihad ^c   Mounzer, Karam ^d   Bruno, Christopher ^e   Hoffman Terry, Margaret ^f   Dorey Stein, Zachariah ^a   Ferrara, Thomas ^b   Kostman, Jay R ^a   Lo Re III, Vincent ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c St Michael's Hospital   (United States)

^d Jonathan Lax Treatment Center   (United States)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f LEHIGH VALLEY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; METHADONE; NELFINAVIR; NEVIRAPINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TENOFOVIR; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DIDEOXYNUCLEOSIDES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77949363604     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1492     Document Type: Article

References (25)

1. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
2. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848.
3. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459.
4. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
5. Barreiro P, Labarga P, Martin-Carbonero L, et al. Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIVcoinfected patients. Antivir Ther 2006; 11:869-877.
6. De Bona A, Galli L, Gallotta G, et al. Rate of cirrhosis progression reduced in HIV/HCV co-infected nonresponders to anti-HCV therapy. New Microbiol 2007; 30:259-264.
7. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196:670-676.
8. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46:622-630.
9. Backus LI, Boothroyd DS, Mole LA. Predictors of sustained virologic response to pegylated interferon and ribavirin in a national cohort of male HIV/HCV-coinfected veterans in routine medical care. Digestive Disease Week (DDW 2009). Chicago. May 30-June 4, 2009 [Abstract M1785].
10. Lo Re V, III, Amorosa VK, Localio AR, et al. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 2009; 48:186-193.
11. Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007; 45:123-125.
12. Laufer N, Laguno M, Perez I, et al. Abacavir does not influence the rate of virological response in HIV-HCVcoinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther 2008; 13:953-957.
13. Mira JA, Lopez-Cortes LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008; 62:1365-1373.
14. Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008; 13:429-437.
15. Pineda JA, Mira JA, Gil Ide L, et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 2007; 60:1347-1354.
16. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
17. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089.
18. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
19. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
21. Tien PC. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. Am J Gastroenterol 2005; 100:2338-2354.
22. Rothman KJ, Greenland S. Modern Epidemiology. 1998. Philadelphia: Lippincott Williams and Wilkins.
23. Chung RT, Umbleja T, Butt AA, et al. SLAM-C (ACTG 5178): Role of early virologic response in extended therapy with PEG-interferon and weight-based ribavirin in HCV/HIV coinfection. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, Canada. Abstract 103LB.
24. Walker AM, Stampfer MJ. Observational studies of drug safety. Lancet 1996; 348:489.
25. Talwani R, Reisler R, Polk C, et al. Ritonavir-boosted PI and not abacavir adversely impacts HCV treatment. 48th International Conference on Antimicrobial Agents and Chemotherapy. 25-28 October 2008, Washington, DC, USA. Abstract V-1632.